Lantern Pharma Inc. (NASDAQ: LTRN) has announced its financial results for the fiscal year and fourth quarter ended December 31, 2025, highlighting significant operational milestones and strategic advancements in its clinical pipeline. The company reported a net loss of approximately $17.1 million for the year, a reduction from the previous year's loss of $20.8 million, reflecting a disciplined approach to managing operating expenses. Total operating expenses decreased by 19% year-over-year, primarily due to reduced research and development costs. Lantern's cash position as of December 31, 2025, stood at approximately $10.1 million, down from $24 million the previous year, indicating a need for additional funding to support ongoing operations and clinical trials.

The company has made notable progress in its clinical programs, particularly with LP-300, which is currently in a Phase 2 trial for non-small cell lung cancer (NSCLC) in never-smokers. Lantern has completed targeted enrollment in Japan and is seeking FDA feedback on proposed protocol amendments aimed at optimizing patient outcomes. Additionally, the company has achieved all primary endpoints in the Phase 1a trial of LP-184, with plans to advance into Phase 1b/2 trials in 2026.

Lantern also announced the FDA clearance of an Investigational New Drug (IND) application for its pediatric CNS cancer trial through its subsidiary, Starlight Therapeutics. This trial is expected to address significant unmet medical needs in rare pediatric cancers. The company is actively exploring collaboration opportunities to maximize the commercial potential of its drug candidates and AI platforms, RADR® and withZeta.ai, which are designed to enhance drug development efficiency.

Looking ahead, Lantern Pharma aims to expand its clinical pipeline and commercial efforts, with several key milestones anticipated in 2026, including additional data readouts from the HARMONIC™ trial and the initiation of new clinical studies. The company will host a conference call on March 30, 2026, to discuss these developments in detail.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.